
Genitourinary Cancers
Latest News

ALLO-316 Produces Responses in Heavily Pretreated Clear Cell Renal Carcinoma
Latest Videos

CME Content
More News

Alan Tan, MD, emphasizes the importance of considering safety profiles and patient-related factors before selecting an IO regimen in metastatic ccRCC.

Alexander Chehrazi-Raffle, MD, details safety data and the clinical implications of an analysis of second-line tivozanib for patients with metastatic RCC.

Naomi B. Haas, MD, shares 5-year follow-up data with adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

A new drug application seeking the Chinese approval of sintilimab plus fruquintinib in second-line advanced/metastatic RCC has been accepted by the NMPA

The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.

Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.

Cabozantinib plus atezolizumab or cabozantinib alone was effective regardless of prior immunotherapy or TKI treatment in second-line advanced RCC.

Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.

First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.

Marc R. Matrana, MD, discusses the ongoing need for validated biomarkers to guide treatment selection in renal cell carcinoma.

Marc Matrana, MD, discusses how the expansion of the frontline RCC treatment paradigm opens the door to further questions regarding personalized treatment.

Joseph Vento, MD, highlights the role of IO/TKI combinations for the treatment of patients with non–clear cell renal cell carcinoma.

Nivolumab has been approved for subcutaneous use across several adult solid tumor indications that have an existing indication for intravenous use.

I. Alex Bowman, MD, discusses the differences in disease presentation between ccRCC and non-ccRCC, as well as standard treatments for these subtypes.

Charles B. Nguyen, MD, discusses the evolving landscape of adjuvant therapy in localized clear cell renal cell carcinoma.

Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.

During an OncLive Peer Exchange filmed during ASCO GU, expert investigators discussed significant updates in the RCC space.

Sitravatinib plus nivolumab did not produce significant antitumor activity or survival outcomes in patients with progressive metastatic clear cell RCC.

Belzutifan was safe and effective in patients with von Hippel-Lindau–associated RCC and other neoplasms.




















































